Skip to main content

Market Overview

What To Make Of The Rumored CVS Bid For Aetna

Share:
What To Make Of The Rumored CVS Bid For Aetna

The big news on Wall Street Thursday afternoon was the potential $66 billion buyout of Aetna Inc (NYSE: AET) by CVS Health Corp (NYSE: CVS). Analysts are looking at the potential deal in terms of how traders should play the two stocks involved.

Aetna stock jumped 11.5 percent following the news of the potential bid, but Cantor Fitzgerald analyst Steven Halper took the opportunity to downgrade Aetna stock from Overweight to Neutral. Halper was previously bullish on Aetna but maintains his price target of $175 for the stock based on its fundamental valuation. Halper said there is enough uncertainty in the potential deal that the $200 rumored takeout price is not worth the risk of buying the stock.

Related Link: Analysis: A CVS-Aetna Merger Would Be Revolutionary

“While we believe that a CVS/AET transaction is not implausible, the risk/reward trade-off given the uncertainty is not attractive,” Halper said.

tipranks.png

From the CVS standpoint, Mizuho analyst Ann Hynes said Friday the deal makes a lot of sense. Mizuho had previously discussed the potential advantages of CVS joining forces with a managed care company earlier this year.

According to Hynes, this merger could serve as a template for the future of the pharmacy retail industry.

“Similar to formulary management in pharmacy, this type of partnership between a retail pharmacy and a managed care company could be the next generation of formulary management in healthcare services,” she wrote.

Mizuho sees an opportunity for CVS to expand its number of MinuteClinics or create mini urgent care centers within CVS stores.

Mizuho maintains its Buy rating for CVS and has a $90 price target for the stock.

tipranks.png

At time of publication, shares of Aetna were down 3.86 percent at $173.23. CVS shares were down 4.05 percent at $70.34.

________

Image Credit: hattiesburgmemory (CVS Pharmacy Uploaded by AlbertHerring) [CC BY 2.0], via Wikimedia Commons

Latest Ratings for CVS

DateFirmActionFromTo
Feb 2022Raymond JamesDowngradesStrong BuyOutperform
Dec 2021Tigress FinancialMaintainsBuy
Dec 2021MizuhoMaintainsBuy

View More Analyst Ratings for CVS

View the Latest Analyst Ratings

 

Related Articles (AET + CVS)

View Comments and Join the Discussion!

Posted-In: Analyst Color Long Ideas M&A Downgrades Price Target Reiteration Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com